Developer docs
API playgroundTry for free, no card

Search company profiles

McKesson Ventures

Full company profile

uuid0003axr

Namestring
McKesson Ventures
Legal namestring
McKesson Corporation
Company typeenum
Private
Founded yearint
2014
Descriptiontext

McKesson Ventures is the corporate venture capital arm of McKesson Corporation (NYSE: MCK), a Fortune 15 pharmaceutical distributor and healthcare IT company. Founded in 2014 by Tom Rodgers, the firm invests in venture and growth-stage companies building innovative software and services for the healthcare and pharmaceutical industries. The fund operates with a small team (1-10 employees) based in San Francisco and deploys capital across two primary investment categories: Pharma Tech Services (data analytics, evidence generation, and commercialization platforms such as Aetion, Atropos Health, Komodo Health, BranchLab, and Prudentia Sciences) and Health-Tech & Tech Enabled Services (care delivery, telehealth, and clinical AI companies such as Aledade, IVX Health, Midi Health, Latent, and Oath Surgical).

The firm's core value proposition is its direct connection to McKesson Corporation's healthcare ecosystem, including the parent's pharmaceutical supply chain (delivering approximately 30% of America's medicines), oncology network (treating 40% of U.S. cancer patients through The US Oncology Network), and relationships with pharmacies, payors, providers, and manufacturers. Portfolio companies gain strategic introductions, domain expertise on U.S. healthcare system mechanics, and access to McKesson subsidiaries including CoverMyMeds, Biologics, and Ontada as ecosystem partners. The firm does not sell a discrete technology product; its "product" is capital plus curated ecosystem access.

McKesson Ventures generates returns through equity investments in healthcare technology startups, with realized exits including Accolade, Amwell, and Hims (IPOs), GRAIL (acquired by Illumina), Landmark (acquired by Optum), Propeller (acquired by ResMed), Xealth (acquired by Samsung Electronics), and RxLightning (acquired by McKesson). In 2025 the firm expanded into growth-stage equity investing by adding a dedicated growth equity function led by Peter Lafer, formerly a Principal at General Atlantic. Recent investment activity has concentrated in AI-enabled healthcare companies — clinical AI (Latent), pharmaceutical commercialization (BranchLab, Prudentia Sciences), and AI-powered surgical care (Oath Surgical) — alongside a unicorn-scale outcome in women's health (Midi Health, $100M Series D at $1B+ valuation in 2026).

Short descriptiontext

McKesson Ventures is McKesson Corporation's corporate venture capital arm, investing in venture and growth-stage healthcare technology and pharma services companies. The firm provides portfolio companies with capital and strategic access to McKesson's healthcare ecosystem spanning pharmaceutical distribution, oncology, and pharmacy operations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, healthcare technology investing, growth equity funding, pharma tech services, healthcare startup funding
Industry1 code
PRIMARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Securities, Commodity Contracts, and Other Financial Investments and Related Activities523
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeLicensing Royalties
Description

McKesson Ventures generates returns through equity investments in healthcare technology startups, benefiting from McKesson's strategic position in the pharmaceutical supply chain and healthcare ecosystem. Returns realized through portfolio company exits via IPO or acquisition.

ventures.mckesson.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

McKesson Ventures is the corporate venture capital arm of McKesson Corporation that invests in venture and growth-stage companies building innovative software and services for the healthcare and pharmaceutical industries. The firm provides capital, strategic guidance, and access to McKesson's extensive healthcare ecosystem, including relationships with pharmacies, payors, providers, and manufacturers. Investment focus spans two primary categories: Pharma Tech Services and Health-Tech & Tech Enabled Services.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

McKesson Ventures is a strategic venture capital firm that invests in innovative software and services companies within the healthcare and pharmaceutical industries. Rather than operating a unified product platform, McKesson Ventures functions as an investment vehicle providing capital, strategic guidance, and access to the broader McKesson healthcare ecosystem to its portfolio companies. The firm's investment focus spans two primary categories: Pharma Tech Services (including companies like Aetion, Atropos Health, BranchLab, Clinical Ink, Komodo Health, Prudentia Sciences, and Saama focused on data analytics, evidence generation, and commercialization) and Health-Tech & Tech Enabled Services (including companies like Aledade, IVX Health, Latent, Midi Health, Oath Surgical, and Reimagine Care focused on care delivery, telehealth, and clinical AI). The portfolio companies maintain their own distinct products and services independently.

Product and service2 records
1Venture Capital Investment Program
CategoryVenture Capital Investing
Description

Equity investment program targeting venture-stage healthcare technology and services companies. Provides capital, strategic guidance, and access to McKesson's healthcare ecosystem including relationships with pharmacies, payors, providers, and manufacturers. Focus areas include data analytics, evidence generation, clinical research, and care delivery.

2Growth Equity Investment Program
CategoryGrowth Equity Investing
Description

Equity investment program targeting growth-stage and profitable healthcare companies. Provides growth capital with strategic partnership to scale operations, enter new markets, and expand offerings. Led by Head of Growth Equity Peter Lafer.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Portfolio company Atropos Health partnered with Guidehouse to jointly develop clinical decision support solutions operationalizing real-world evidence for clinical and life sciences teams.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Portfolio company Aledade partnered with Doximity to integrate Scribe and Ask AI technologies into Aledade Assist electronic health overlay for value-based care settings.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-07-08
Description

Portfolio company Xealth was acquired by Samsung Electronics to combine wearable technology with Xealth's digital health platform, bridging wellness and medical care.

4The US Oncology Network
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership supporting community-based specialty oncology practices through McKesson's connected network of cancer care providers.

ventures.mckesson.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership enabling patient enrollment in oncology clinical trials as part of McKesson's comprehensive cancer care ecosystem.

6CoverMyMeds
Strategic tierCoreTypeStrategic or Co-development Partner
Description

McKesson subsidiary providing medication access solutions including electronic prior authorization, e-prescribing, and patient support programs.

ventures.mckesson.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Specialty pharmacy services supporting patients on 200+ specialty therapies as part of McKesson's comprehensive pharmacy ecosystem.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

McKesson subsidiary providing community oncology real-world data and evidence for research and clinical decision support.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large global growth equity firm with deep healthcare investing practice. McKesson Ventures' Head of Growth Equity Peter Lafer was previously a Principal at General Atlantic, indicating talent and strategy overlap.

TypeDirect peer
Description

CVC arm of CVS Health, investing in healthcare technology startups. Provides similar strategic value proposition combining capital with healthcare ecosystem access (pharmacy, insurance, providers).

TypeDirect peer
Description

CVC arm of UnitedHealth Group's Optum, one of the largest healthcare CVCs. Invests across healthcare services, technology, and care delivery with strategic ecosystem access comparable to McKesson Ventures.

TypeBroad incumbent
Description

Established venture capital firm with significant healthcare practice. While broader than McKesson Ventures' healthcare-exclusive focus, it competes for similar growth-stage healthcare software and services investments.

TypeDirect peer
Description

CVC of major pharmacy and healthcare company, investing in digital health and tech-enabled care delivery. Comparable CVC structure with retail pharmacy ecosystem access.

TypeDirect peer
Description

Healthcare-focused venture and growth equity firm investing across care delivery, technology, and services. Co-invested with McKesson Ventures in Lumata Health Series B, showing direct syndicate overlap.

TypeDirect peer
Description

Strategic CVC investing in healthcare innovation, formed as a partnership between Cambia Health Solutions and Mosaic Health Solutions. Operates with similar CVC mandate focused on healthcare transformation and portfolio ecosystem support.

TypeDirect peer
Description

Healthcare-focused CVC associated with Kaiser Permanente, invests in healthcare technology and services. Notably, McKesson Ventures President Dave Schulte previously led Kaiser Permanente Ventures, establishing direct personnel and strategy overlap.

TypeDirect peer
Description

CVC arm of Cardinal Health, another top-tier pharmaceutical distributor competing directly with McKesson. Invests in healthcare technology with similar strategic rationale.

TypeDirect peer
Description

Corporate venture arm of Cencora (formerly AmerisourceBergen), one of the largest pharma distributors and direct competitor to McKesson. Invests in healthcare tech and pharma services with similar CVC structure and ecosystem access.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment63 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

McKesson Ventures

Healthcare Venture Capitalventures.mckesson.com

McKesson Ventures is McKesson Corporation's corporate venture capital arm, investing in venture and growth-stage healthcare technology and pharma services companies. The firm provides portfolio companies with capital and strategic access to McKesson's healthcare ecosystem spanning pharmaceutical distribution, oncology, and pharmacy operations.

What McKesson Ventures does

McKesson Ventures is the corporate venture capital arm of McKesson Corporation (NYSE: MCK), a Fortune 15 pharmaceutical distributor and healthcare IT company. Founded in 2014 by Tom Rodgers, the firm invests in venture and growth-stage companies building innovative software and services for the healthcare and pharmaceutical industries. The fund operates with a small team (1-10 employees) based in San Francisco and deploys capital across two primary investment categories: Pharma Tech Services (data analytics, evidence generation, and commercialization platforms such as Aetion, Atropos Health, Komodo Health, BranchLab, and Prudentia Sciences) and Health-Tech & Tech Enabled Services (care delivery, telehealth, and clinical AI companies such as Aledade, IVX Health, Midi Health, Latent, and Oath Surgical).

The firm's core value proposition is its direct connection to McKesson Corporation's healthcare ecosystem, including the parent's pharmaceutical supply chain (delivering approximately 30% of America's medicines), oncology network (treating 40% of U.S. cancer patients through The US Oncology Network), and relationships with pharmacies, payors, providers, and manufacturers. Portfolio companies gain strategic introductions, domain expertise on U.S. healthcare system mechanics, and access to McKesson subsidiaries including CoverMyMeds, Biologics, and Ontada as ecosystem partners. The firm does not sell a discrete technology product; its "product" is capital plus curated ecosystem access.

McKesson Ventures generates returns through equity investments in healthcare technology startups, with realized exits including Accolade, Amwell, and Hims (IPOs), GRAIL (acquired by Illumina), Landmark (acquired by Optum), Propeller (acquired by ResMed), Xealth (acquired by Samsung Electronics), and RxLightning (acquired by McKesson). In 2025 the firm expanded into growth-stage equity investing by adding a dedicated growth equity function led by Peter Lafer, formerly a Principal at General Atlantic. Recent investment activity has concentrated in AI-enabled healthcare companies — clinical AI (Latent), pharmaceutical commercialization (BranchLab, Prudentia Sciences), and AI-powered surgical care (Oath Surgical) — alongside a unicorn-scale outcome in women's health (Midi Health, $100M Series D at $1B+ valuation in 2026).

McKesson Ventures firmographics

Firmographics
Name
McKesson Ventures
Legal name
McKesson Corporation
Website
https://ventures.mckesson.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
McKesson Ventures is McKesson Corporation's corporate venture capital arm, investing in venture and growth-stage healthcare technology and pharma services companies. The firm provides portfolio companies with capital and strategic access to McKesson's healthcare ecosystem spanning pharmaceutical distribution, oncology, and pharmacy operations.
Ownership category
akta.pro rank

McKesson Ventures industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms

Keywords

  • Venture capital investing
  • Healthcare technology investing
  • Growth equity funding
  • Pharma tech services
  • Healthcare startup funding

Where McKesson Ventures is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

McKesson Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Investment Returns: McKesson Ventures generates returns through equity investments in healthcare technology startups, benefiting from McKesson's strategic position in the pharmaceutical supply chain and healthcare ecosystem. Returns realized through portfolio company exits via IPO or acquisition.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

McKesson Ventures product offering

Product offering

Core offering

McKesson Ventures is the corporate venture capital arm of McKesson Corporation that invests in venture and growth-stage companies building innovative software and services for the healthcare and pharmaceutical industries. The firm provides capital, strategic guidance, and access to McKesson's extensive healthcare ecosystem, including relationships with pharmacies, payors, providers, and manufacturers. Investment focus spans two primary categories: Pharma Tech Services and Health-Tech & Tech Enabled Services.

Product overview

McKesson Ventures is a strategic venture capital firm that invests in innovative software and services companies within the healthcare and pharmaceutical industries. Rather than operating a unified product platform, McKesson Ventures functions as an investment vehicle providing capital, strategic guidance, and access to the broader McKesson healthcare ecosystem to its portfolio companies. The firm's investment focus spans two primary categories: Pharma Tech Services (including companies like Aetion, Atropos Health, BranchLab, Clinical Ink, Komodo Health, Prudentia Sciences, and Saama focused on data analytics, evidence generation, and commercialization) and Health-Tech & Tech Enabled Services (including companies like Aledade, IVX Health, Latent, Midi Health, Oath Surgical, and Reimagine Care focused on care delivery, telehealth, and clinical AI). The portfolio companies maintain their own distinct products and services independently.

Differentiator

Problem solved

Functional benefit

Products and services

  • Venture Capital Investment Program Equity investment program targeting venture-stage healthcare technology and services companies. Provides capital, strategic guidance, and access to McKesson's healthcare ecosystem including relationships with pharmacies, payors, providers, and manufacturers. Focus areas include data analytics, evidence generation, clinical research, and care delivery.
  • Growth Equity Investment Program Equity investment program targeting growth-stage and profitable healthcare companies. Provides growth capital with strategic partnership to scale operations, enter new markets, and expand offerings. Led by Head of Growth Equity Peter Lafer.

Companies that use McKesson Ventures

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

McKesson Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

McKesson Ventures partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered strategic and core.

  • GuidehousestrategicStrategic or Co-development Partner · 18 May 2026Portfolio company Atropos Health partnered with Guidehouse to jointly develop clinical decision support solutions operationalizing real-world evidence for clinical and life sciences teams.
  • DoximitystrategicStrategic or Co-development Partner · 13 May 2026Portfolio company Aledade partnered with Doximity to integrate Scribe and Ask AI technologies into Aledade Assist electronic health overlay for value-based care settings.
  • Samsung ElectronicsstrategicStrategic or Co-development Partner · 8 July 2025Portfolio company Xealth was acquired by Samsung Electronics to combine wearable technology with Xealth's digital health platform, bridging wellness and medical care.
  • The US Oncology NetworkcoreStrategic or Co-development PartnerStrategic partnership supporting community-based specialty oncology practices through McKesson's connected network of cancer care providers.
  • US Oncology Research (SCRI)coreStrategic or Co-development PartnerPartnership enabling patient enrollment in oncology clinical trials as part of McKesson's comprehensive cancer care ecosystem.
  • CoverMyMedscoreStrategic or Co-development PartnerMcKesson subsidiary providing medication access solutions including electronic prior authorization, e-prescribing, and patient support programs.
  • BiologicscoreStrategic or Co-development PartnerSpecialty pharmacy services supporting patients on 200+ specialty therapies as part of McKesson's comprehensive pharmacy ecosystem.
  • OntadacoreStrategic or Co-development PartnerMcKesson subsidiary providing community oncology real-world data and evidence for research and clinical decision support.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

McKesson Ventures competitors and assessment

Company assessment

Broad incumbents

  • General Atlantic: Large global growth equity firm with deep healthcare investing practice. McKesson Ventures' Head of Growth Equity Peter Lafer was previously a Principal at General Atlantic, indicating talent and strategy overlap.
  • Bessemer Venture Partners: Established venture capital firm with significant healthcare practice. While broader than McKesson Ventures' healthcare-exclusive focus, it competes for similar growth-stage healthcare software and services investments.

Direct peers

  • CVS Health Ventures: CVC arm of CVS Health, investing in healthcare technology startups. Provides similar strategic value proposition combining capital with healthcare ecosystem access (pharmacy, insurance, providers).
  • Optum Ventures: CVC arm of UnitedHealth Group's Optum, one of the largest healthcare CVCs. Invests across healthcare services, technology, and care delivery with strategic ecosystem access comparable to McKesson Ventures.
  • Walgreens Boots Alliance Ventures: CVC of major pharmacy and healthcare company, investing in digital health and tech-enabled care delivery. Comparable CVC structure with retail pharmacy ecosystem access.
  • LRVHealth: Healthcare-focused venture and growth equity firm investing across care delivery, technology, and services. Co-invested with McKesson Ventures in Lumata Health Series B, showing direct syndicate overlap.
  • Echo Health Ventures: Strategic CVC investing in healthcare innovation, formed as a partnership between Cambia Health Solutions and Mosaic Health Solutions. Operates with similar CVC mandate focused on healthcare transformation and portfolio ecosystem support.
  • Kaiser Permanente Ventures: Healthcare-focused CVC associated with Kaiser Permanente, invests in healthcare technology and services. Notably, McKesson Ventures President Dave Schulte previously led Kaiser Permanente Ventures, establishing direct personnel and strategy overlap.
  • Cardinal Health Ventures: CVC arm of Cardinal Health, another top-tier pharmaceutical distributor competing directly with McKesson. Invests in healthcare technology with similar strategic rationale.
  • Cencora Ventures: Corporate venture arm of Cencora (formerly AmerisourceBergen), one of the largest pharma distributors and direct competitor to McKesson. Invests in healthcare tech and pharma services with similar CVC structure and ecosystem access.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

McKesson Ventures social profiles

Digital presence

McKesson Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

McKesson Ventures leadership team

Management profile

Number of profiles

Profiles14 records

McKesson Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

McKesson Ventures M&A and investment

M&A and investment

M&A1 record

Investments63 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about McKesson Ventures

What does McKesson Ventures do?

McKesson Ventures is the corporate venture capital arm of McKesson Corporation that invests in venture and growth-stage companies building innovative software and services for the healthcare and pharmaceutical industries. The firm provides capital, strategic guidance, and access to McKesson's extensive healthcare ecosystem, including relationships with pharmacies, payors, providers, and manufacturers. Investment focus spans two primary categories: Pharma Tech Services and Health-Tech & Tech Enabled Services.

Is McKesson Ventures a public or private company?

McKesson Ventures is a private company. It is classified as corporate owned and is currently operating.

When was McKesson Ventures founded?

McKesson Ventures was founded in 2014. It employs 1 to 10 people.

Where is McKesson Ventures based?

McKesson Ventures is headquartered in San Francisco, United States, in the North America region.

How does McKesson Ventures make money?

One revenue line is on record: investment Returns.

Who are McKesson Ventures's main competitors?

Broad incumbents on record are General Atlantic and Bessemer Venture Partners. Direct peers are CVS Health Ventures, Optum Ventures, Walgreens Boots Alliance Ventures, LRVHealth, Echo Health Ventures, Kaiser Permanente Ventures, Cardinal Health Ventures and Cencora Ventures.

Does McKesson Ventures have an API?

No public API is recorded for McKesson Ventures.

What industry is McKesson Ventures in?

McKesson Ventures's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAHAF, Corporate Strategic Partnership & Ecosystem Investment Arms. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Latent Expands AI Pharmacy Platform To 60 Health Systems Serving 70 Million PatientsLatent expanded its pharmacy intelligence platform to 60 U.S. health systems serving 70 million patients, adding autonomous clinical agents for medication access. The company is on pace to process over 5.8 million patient medication cases in 12 months, targeting GLP-1 and specialty therapies.Tracxn2026 Funding Rounds & List of InvestorsMatternet's funding rounds from 2013 to 2026 are listed, including a post-IPO round in May 2026 and a conventional debt round in March 2026. The rounds show varying amounts and lead investors, with RattanIndia Finance and McKesson Ventures among the lead investors.The Manila TimesInvestors and Entrepreneurs Agree: AI, Enterprise Demand and Investor Confidence Are Reshaping Pharma Tech, According to New McKesson Ventures ReportMcKesson Ventures released a report on Aug. 25, 2026, surveying more than 100 healthcare investors and entrepreneurs on pharma technology trends. About 63% of investors said interest in pharma tech rose relative to other healthcare segments, while nearly half of entrepreneurs said the sales environment has improved. Respondents cited AI adoption, usage- and outcomes-based pricing, and clinical trial tools as key drivers.FinancialContent Business PageInvestors and Entrepreneurs Agree: AI, Enterprise Demand and Investor Confidence Are Reshaping Pharma Tech, According to New McKesson Ventures ReportMcKesson Ventures released a report on August 25, 2026, surveying more than 100 healthcare investors and founders on pharma tech trends, finding over 60% of investors report increased interest in pharma tech relative to other healthcare sectors. Entrepreneurs cite easier sales environments, stronger executive sponsorship and faster pilot-to-production transitions. About 75% of companies report changing pricing to usage- or outcomes-based models.Business Wire BlogOath Surgical Performs First Outpatient Robotic Prostatectomy in the U.S. Pacific NorthwestOath Surgical completed the first outpatient robotic prostatectomy in the U.S. Pacific Northwest at its Beaverton, Oregon center. The procedure can save up to $20,000 per case, and Oath plans to expand its network with more centers opening in 2026.VenturecapitalBranchLab Secures $26 Million Series A Financing to Transform Pharma Commercialization with AI PlatformBranchLab raised $26 million in Series A financing led by McKesson Ventures, with participation from FCA Venture Partners, Sanofi Ventures, and AIX Ventures. The company's AI platform for pharma commercialization has driven a nearly 70% increase in marketing efficacy. The funding will support enterprise expansion and deeper integrations.PR NewswireBranchLab Raises $26M Series A Led by McKesson Ventures to Bring AI to Pharma CommercializationBranchLab, a Boulder-based AI platform for pharmaceutical commercialization, announced a $26 million Series A funding round led by McKesson Ventures, with participation from FCA Venture Partners, Sanofi Ventures, and AIX Ventures, bringing total funding to $35 million. The company's platform consolidates patient identification, audience segmentation, and real-world measurement into a unified, privacy-first system, reporting an average increase of nearly 70% in marketing efficacy across therapeutic areas. BranchLab plans to use the proceeds to expand enterprise deployments and deepen integrations across the healthcare and media ecosystem.TechStartupsLyrie.ai launches real-time zero-day tracking as AI agents emerge as the next cybersecurity battlegroundLyrie.ai launched a real-time zero-day tracking and disclosure system to identify vulnerabilities before public exploits. The company also released the open Agent Trust Protocol for verifying AI agent identities and was accepted into Anthropic's Cyber Verification Program.TechStartupsBranchLab raises $26M to transform pharma commercialization with privacy-first AIBranchLab raised $26 million in a Series A round led by McKesson Ventures, bringing total funding to $35 million. The company's privacy-first AI platform claims to increase marketing efficacy by nearly 70% across therapeutic areas. It plans to use the funds to expand enterprise deployments and deepen integrations.TechStartupsGoogle and SpaceX in talks to launch orbital AI data centers into spaceGoogle is in advanced talks with SpaceX to launch AI data centers into orbit, aiming to bypass terrestrial power and land constraints. Google's Project Suncatcher targets satellites for deployment as early as 2027, and Google invested roughly $900 million in SpaceX in 2015. The effort could reshape AI infrastructure, though technical hurdles remain.